Intravitreal Administration of the Anti-Tumor Necrosis Factor Agent Infliximab for Neovascular Age-related Macular Degeneration
To access this article, please choose from the options below
See accompanying Editorial on page 761.
PII: S0002-9394(08)00921-5
doi:10.1016/j.ajo.2008.12.004
© 2009 Elsevier Inc. All rights reserved.
Refers to article:
- When Is Off-Label Drug Use in the Patient's Best Interest?
